Symbios Health Limited 13065822 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of occupational health services. Digita Accounts Production Advanced 6.30.9574.0 true 13065822 2024-04-01 2025-03-31 13065822 2025-03-31 13065822 core:CurrentFinancialInstruments 2025-03-31 13065822 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 13065822 core:FurnitureFittings 2025-03-31 13065822 core:PlantMachinery 2025-03-31 13065822 1 2025-03-31 13065822 bus:SmallEntities 2024-04-01 2025-03-31 13065822 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 13065822 bus:FilletedAccounts 2024-04-01 2025-03-31 13065822 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 13065822 bus:RegisteredOffice 2024-04-01 2025-03-31 13065822 bus:Director1 2024-04-01 2025-03-31 13065822 bus:Director2 2024-04-01 2025-03-31 13065822 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 13065822 core:FurnitureFittings 2024-04-01 2025-03-31 13065822 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 13065822 core:PlantMachinery 2024-04-01 2025-03-31 13065822 core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity 2024-04-01 2025-03-31 13065822 countries:EnglandWales 2024-04-01 2025-03-31 13065822 1 2024-04-01 2025-03-31 13065822 2024-03-31 13065822 core:FurnitureFittings 2024-03-31 13065822 core:PlantMachinery 2024-03-31 13065822 1 2024-03-31 13065822 2023-01-01 2024-03-31 13065822 2024-03-31 13065822 core:CurrentFinancialInstruments 2024-03-31 13065822 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 13065822 core:FurnitureFittings 2024-03-31 13065822 core:PlantMachinery 2024-03-31 13065822 1 2024-03-31 13065822 1 2023-01-01 2024-03-31 13065822 1 2022-12-31 iso4217:GBP xbrli:pure

Registration number: 13065822

Symbios Health Limited
Unaudited Filleted Financial Statements
for the Year Ended 31 March 2025

Symbios Health Limited

Contents

Statement of Financial Position | 1
Notes to the Unaudited Financial Statements | 2 to 7

Symbios Health Limited

(Registration number: 13065822)
Statement of Financial Position as at 31 March 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Tangible assets | 4 | 27,909 | 29,214
Current assets |  |  |
Debtors | 5 | 400,253 | 245,421
Cash at bank and in hand |  | 108,375 | 258,710
|  | 508,628 | 504,131
Creditors: Amounts falling due within one year | 6 | (142,172) | (110,542)
Net current assets |  | 366,456 | 393,589
Total assets less current liabilities |  | 394,365 | 422,803
Provisions for liabilities |  | (7,371) | (7,304)
Net assets |  | 386,994 | 415,499
Capital and reserves |  |  |
Called up share capital |  | 100 | 102
Capital redemption reserve |  | 2 | -
Profit and loss account |  | 386,892 | 415,397
Shareholders' funds |  | 386,994 | 415,499

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Statement of Comprehensive Income.

Approved and authorised by the Board on 24 June 2025 and signed on its behalf by:

Dr J Whittle Director | Dr O Cooper Director

Symbios Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Plym House
3 Longbridge Road
Plymouth
Marsh Mills
Devon
PL6 8LT

Principal activity

The principal activity of the company is that of occupational health services.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost basis.

The financial statements are prepared in sterling which is the functional currency of the entity.

Symbios Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025 (continued)

2 | Accounting policies (continued)

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on dispatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefit will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
When the outcome of a transaction involving the rendering of services can be reliably estimated, revenue from the rendering of services is measured by reference to the stage of completion of the service transaction at the end of the reporting period.

Tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Symbios Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025 (continued)

2 | Accounting policies (continued)

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Plant and machinery | 20% reducing balance
Fittings fixtures and equipment | 20% reducing balance

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value. In the statement of financial position, bank overdrafts are shown within borrowing or current liabilities

Provisions

Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.
Provisions are initially measured at the best estimate of the amount required to settle the obligation at the current reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, The unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.

Financial instruments

Recognition and measurement
A financial asset or a financial liability is recognised only when the company becomes party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 8 (2024 - 9).

Symbios Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025 (continued)

4 | Tangible assets

| Fixtures and fittings £ | Plant and machinery £ | Total £
Cost or valuation
At 1 April 2024 | 12,382 | 28,308 | 40,690
Additions | 3,750 | 1,919 | 5,669
At 31 March 2025 | 16,132 | 30,227 | 46,359
Depreciation
At 1 April 2024 | 3,698 | 7,778 | 11,476
Charge for the year | 2,484 | 4,490 | 6,974
At 31 March 2025 | 6,182 | 12,268 | 18,450
Carrying amount
At 31 March 2025 | 9,950 | 17,959 | 27,909
At 31 March 2024 | 8,684 | 20,530 | 29,214

Symbios Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025 (continued)

5 | Debtors

| Note | 2025 £ | 2024 £
Trade debtors |  | 160,046 | 128,283
Amounts owed by related parties | 8 | 234,970 | -
Other debtors |  | - | 116,000
Prepayments |  | 5,237 | 1,138
|  | 400,253 | 245,421

6 | Creditors

Creditors: amounts falling due within one year

| 2025 £ | 2024 £
Due within one year |  |
Taxation and social security | 134,057 | 102,853
Accruals and deferred income | 5,750 | 3,000
Other creditors | 2,365 | 4,689
| 142,172 | 110,542

7 | Reserves

Profit and loss account:
This reserve records retained earnings and accumulated losses.

Symbios Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025 (continued)

8 | Related party transactions

Transactions with directors

2024 | At 1 January 2023 £ | Advances to director £ | Repayments by director £ | At 31 March 2024 £
| 54,573 | 181,936 | (120,509) | 116,000

2025 | At 1 April 2024 £ | Advances to director £ | Repayments by director £ | At 31 March 2025 £
| 116,000 | - | (116,000) | -

Interest is charged on overdrawn balances at the HMRC official rate of interest.

Summary of transactions with all entities with joint control or significant interest

At the reporting date the company was owed £234,970 by companies under the common control of the directors. These balances are unsecured, interest free and repayable on demand.